Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 9/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968011 | 0.83 | EGLN1 (0.55) | EGLN1EGLN2BBOX1FTO | |
| SCHEMBL2898413 | 0.72 | EGLN1 (0.38) | EGLN1BBOX1FTO | |
| SCHEMBL2893699 | 0.69 | EGLN1 (0.41) | EGLN1EGLN2MAOAFTO | |
| SCHEMBL2896550 | 0.69 | EGLN1 (0.38) | EGLN1MAOAHDAC6 | |
| SCHEMBL522600 | 0.68 | EGLN2 (0.63) | EGLN1EGLN2MAOABBOX1FTO | |
| SCHEMBL522390 | 0.68 | EGLN2 (0.63) | EGLN1EGLN2MAOABBOX1FTO | |
| SCHEMBL522391 | 0.68 | EGLN2 (0.63) | EGLN1EGLN2MAOABBOX1FTO | |
| SCHEMBL2896782 | 0.68 | EGLN1 (0.41) | EGLN1MAOABBOX1FTO | |
| SCHEMBL4499594 | 0.68 | EGLN2 (0.66) | EGLN1EGLN2MAOA | |
| SCHEMBL525577 | 0.66 | EGLN1 (0.48) | EGLN1EGLN2BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885MAOA 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.